Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced parkinson disease

Clinical Neuropharmacology

Volumn 33, Issue 3, 2010, Pages 135-141

  Adamiak, Urszula ^a   Kaldonska, Maria ^a   Klodowska Duda, Gabriela ^b   Wyska, Elzbieta ^c   Safranow, Krzysztof ^a   Bialecka, Monika ^a   Gawronska Szklarz, Barbara ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Levodopa; Parkinson disease; Pharmacokinetic pharmakodynamic modeling; Tolcapone

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; TOLCAPONE;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DYSKINESIA; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; BENSERAZIDE; BENZOPHENONES; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; DOPA DECARBOXYLASE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSKINESIAS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; LEVODOPA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NITROPHENOLS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TYROSINE;

EID: 77953135125     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181d47849     Document Type: Article

References (31)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-2066.
2. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-2476.
3. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's Disease. Clin Pharmacokinet 2002;41:261-309.
4. Marsden CD. Parkinson's disease. J Neurol Neurosurg 1994;57:672-681.
5. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23 (suppl 3) : S580-S584.
6. Bhidayasiri R, Truong DD. Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 2008;266:204-215.
7. Stern MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease. Neurology 1997;49 (suppl) : S2-S9.
8. Di Stefano A, Sozio P, Iannitelli A, et al. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv 2009;6(4):389-404.
9. Harder S, Baas H. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clin Pharmacol Ther 1998;64:183-191.
10. Saxer C, Niina M, Nakashima A, et al. Simultaneous determination of lewodopa and 3-O-methyldopa in human plasma by liquid chromatography with electrochemical detection. J Chromatogr B 2004;802:299-305.
11. Baas H, Zehrden F, Selzer R, et al. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokinet 2001;40:383-393. (Pubitemid 32565598)
12. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Neurology 2006;66:968-975.
13. Contin M, Riva R, Martinelli P, et al. Pharmacodynamic modeling of oral levodopa. Neurology 1993;43:367-371.
14. Bredberg E, Tedroff J, Aquilonius SM, et al. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:385-389.
15. Nelson MV, Berchou RC, LeWitt PA, et al. Pharmacodynamic modeling of concentration-effect relationships after controlled release carbidopa/levodopa in Parkinson's disease. Neurology 1990;40:70-74.
16. Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 1995;29:243-256.
17. Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996;51:59-67.
18. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 2006;45:109-136.
19. Li Y, Wirth T, Huotari M. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. Eur J Clin Pharmacol 1998;356:127-137.
20. Zurcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibition of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New Developments in Therapy of Parkinson's Disease. Rome: John Libbry; 1919:37-43.
21. Gervas JJ, Muradas V, Bazan E. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983;33:278-282.
22. Nutt JG, Woodward WR, Gancher ST. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987;21:584-588.
23. Cedarbaum JM, Kutt H, McDowell FH. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988;38:533-536.
24. Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-559.
25. Leenders KL, Salmom EP, Turton DR, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and patients with Parkinson's disease. Arch Neurol 1990;30:24-30.
26. Goetz CG. Influence of COMT inhibition of levodopa pharmacology and therapy. Neurology 1998;50 (suppl 5) : S26-S30.
27. Jorga KM. Pharmacokinetics, pharmacodynamics and tolerability of tolcapone: a review of early studies in volunteers. Neurology 1998;50 (suppl 5) : S31-S38.
28. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
29. Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 2005;4:69-73.
30. Sedek G, Jorga K, Schmitt M, et al. Effect of tolcapone on plasma levodopa concentration after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 1997;20:531-541.
31. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-1250.